# BPC-157 Legal Status, FDA 503A Category, and Compounding Access > BPC-157 legal status, plainly stated: not an FDA-approved drug, placed by FDA in 503A Category 2 (effective Sept 29, 2023), and individually named on the FDA PCAC agenda for July 23-24, 2026 as a substance under evaluation. General information, cited to FDA. Where the access question stands today, anchored to FDA's own pages — and what is genuinely on the calendar for 2026, stated as a scheduled discussion and nothing more. ## The momentum: BPC-157 access is under active FDA review and may expand in 2026 BPC-157 legal status is, for the first time in years, a moving question — and the movement is on FDA's own calendar. BPC-157 is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, where it is listed — as the entries "BPC-157 (free base)" and "BPC-157 acetate" — among bulk drug substances "being considered for inclusion on the 503A Bulks List" [11]. The same agenda lists KPV, TB-500, and MOTs-C. That is the news, and it is real: a substance that has spent years outside the compounding framework is now scheduled for formal evaluation toward it. It is worth being exact about what that meeting is and is not. A PCAC discussion is a step in evaluation — the committee advises FDA; it does not decide. Being on the agenda means BPC-157 is under active review, not that anything has been listed, reclassified, or changed [11]. Access may expand in 2026; whether it does is a question the calendar raises and only a later FDA action could answer. This page leads with the momentum because the momentum is genuine, and stops short of an outcome because no outcome exists yet. ## The current fact: BPC-157 is in 503A Category 2 and is not an approved drug As of today the established fact is this: FDA identified BPC-157 — under the list entries "BPC-157 (free base)" and "BPC-157 acetate" — as a bulk drug substance that may present significant safety risks, and placed it in Category 2 for 503A compounding, effective with FDA's September 29, 2023 update to the list of nominated bulk drug substances [12]. FDA's stated concerns include potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [12]. Two consequences follow directly, and both are present-tense. Because BPC-157 is a Category 2 substance, it is not within FDA's enforcement-discretion policy for 503A compounding — the policy that covers Category 1 substances does not extend to it [12][13]. And separately, BPC-157 is not an FDA-approved drug: approval of a finished drug is a different question from compounding eligibility, and BPC-157 has cleared neither bar [13]. The July 2026 agenda does not alter this current status; it schedules a discussion of it [11]. ## How the 503A and 503B framework works The relevant law is the federal compounding framework. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [13]. A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an approved finished drug — only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [13]. Substances not yet on a bulks list are evaluated by FDA through a public nomination process, with input from PCAC. FDA's interim policy sorted nominated substances into Category 1 (covered by enforcement discretion while under evaluation) and Category 2 (identified as raising significant safety risks, and not afforded that discretion) [13]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer places newly nominated substances into these numbered categories; substances already in Category 2 are not afforded discretion even if their nominations are updated [13]. Being discussed by PCAC, as BPC-157 is scheduled to be in July 2026, is a step in that evaluation — not a final listing decision [11][13]. ## How legally compounded peptide access works, in general In general terms, a legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [13]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [13]. Telehealth can serve as the front-end channel through which the patient evaluation and prescription occur — but it is a route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances are eligible to be compounded [13]. The ingredient-eligibility caveat is the part that bears on BPC-157 specifically. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules; an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [13]. As long as BPC-157 remains in Category 2, that caveat applies to it. This is a description of the lawful pathway and the present constraint — not advice to obtain any substance, and not a route around the framework. ## What this page does not claim Two claims circulating online are deliberately not made here. The first is that an early-2026 reclassification has already occurred — that roughly fourteen of the peptides placed in Category 2 in 2023 have moved back toward Category 1. That could not be confirmed as a completed, effective action from an authoritative FDA source, and the most candid sources making the claim acknowledge the formal reclassification was still pending [12]. The second is that BPC-157 was specifically "removed" from Category 2 on a dated occasion in 2026; that, too, could not be verified from FDA, and is in tension with BPC-157 still appearing on the July 2026 PCAC agenda as a candidate under consideration [11][12]. So the record this page keeps is the conservative one: Category 2 today, a scheduled PCAC discussion in July 2026, and no reclassification stated as done, dated, or certain. BPC-157 is also prohibited in sport at all times by the World Anti-Doping Agency, a separate consideration relevant to athletes. Everything here is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance. ## Is BPC-157 legal? BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances it identified as potentially presenting significant safety risks — effective with its September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for 503A compounding [12][13]. It is separately prohibited in sport at all times by the World Anti-Doping Agency. "Legal" is not a single yes or no here: BPC-157 is not approved, not currently within the compounding-discretion framework, and is named for evaluation on the July 2026 PCAC agenda [11]. ## Can you get BPC-157 from a compounding pharmacy? As of today, BPC-157's Category 2 status means it is not eligible for routine 503A compounding while that status stands [12][13]. A legally compounded preparation requires an eligible active ingredient plus a licensed-prescriber evaluation and a valid, patient-specific prescription, dispensed by a 503A pharmacy or sourced from a 503B outsourcing facility [13]. The ingredient-eligibility step is exactly where BPC-157's current status applies. FDA has scheduled a July 2026 PCAC discussion of the compound, but that is an evaluation, not a change in status [11]. ## What is the FDA 503A status of BPC-157? FDA placed BPC-157 (the list entries "BPC-157 (free base)" and "BPC-157 acetate") in 503A Category 2, effective with its September 29, 2023 update to the nominated bulk-drug-substances list, citing concerns including potential immunogenicity for certain routes and peptide impurity/characterization complexity [12]. Category 2 substances are not afforded FDA's enforcement discretion for 503A compounding [13]. BPC-157 is also named on the July 23-24, 2026 PCAC agenda as a substance being considered for the 503A bulks list — a scheduled discussion, not a listing decision [11]. --- A stained-glass reading of the BPC-157 record — each finding set in its own pane, cited to the source, with no clinic behind the glass and nothing here for sale.